# Marc Humbert

List of Publications by Year
in descending order



| 848 | 91,263 | 397 133 | 442 274 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 933 | 933 | 933 | 47518 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 2016, 37, 67-119. | 1.0 | 5,074 |
| 2 | Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537. | 1.0 | 3,108 |
| 3 | 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080. | 1.0 | 2,591 |
| 4 | 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal, 2020, 41, 543-603. | 1.0 | 2,426 |
| 5 | 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal, 2015, 46, 903-975. | 3.1 | 2,415 |
| 6 | Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1198-1207. | 13.9 | 1,807 |
| 7 | Pulmonary Arterial Hypertension in France. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1023-1030. | 2.5 | 1,736 |
| 8 | Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2004, 351, 1425-1436. | 13.9 | 1,627 |
| 9 | Cellular and molecular pathobiology of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S13-S24. | 1.2 | 1,322 |
| 10 | Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. Journal of the American College of Cardiology, 2002, 40, 780-788. | 1.2 | 1,290 |
| 11 | Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163. | 1.6 | 1,264 |
| 12 | Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340. | 13.9 | 1,120 |
| 13 | Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2005, 111, 3105-3111. | 1.6 | 1,040 |
| 14 | New Formula for Predicting Mean Pulmonary Artery Pressure Using Systolic Pulmonary Artery Pressure. Chest, 2004, 126, 1313-1317. | 0.4 | 923 |
| 15 | Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278. | 1.0 | 903 |
| 16 | The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic. Chest, 2020, 158, 106-116. | 0.4 | 832 |
| 17 | 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647. | 3.1 | 806 |
| 18 | Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. European Respiratory Journal, 2019, 53, 1801887. | 3.1 | 776 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal, 2016, 47, 410-419. | 3.1 | 746 |
| 20 | After asthma: redefining airways diseases. Lancet, The, 2018, 391, 350-400. | 6.3 | 744 |
| 21 | The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology, 2020, 296, 172-180. | 3.6 | 721 |
| 22 | Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 165-175. | 2.0 | 708 |
| 23 | Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334. | 13.9 | 676 |
| 24 | Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis and Rheumatism, 2005, 52, 3792-3800. | 6.7 | 656 |
| 25 | Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. JAMA Internal Medicine, 2021, 181, 32. | 2.6 | 654 |
| 26 | Pathologic assessment of vasculopathies in pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S25-S32. | 1.2 | 609 |
| 27 | Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19. | 1.2 | 605 |
| 28 | Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology, 2002, 39, 1496-1502. | 1.2 | 584 |
| 29 | Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555. | 3.1 | 582 |
| 30 | Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137. | 1.6 | 548 |
| 31 | Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889. | 3.1 | 527 |
| 32 | A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322. | 5.2 | 523 |
| 33 | BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. American Journal of Human Genetics, 2001, 68, 92-102. | 2.6 | 521 |
| 34 | Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062. | 1.5 | 486 |
| 35 | Severe Pulmonary Hypertension during Pregnancy. Anesthesiology, 2005, 102, 1133-1137. | 1.3 | 483 |
| 36 | Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation, 2001, 108, 1141-1150. | 3.9 | 446 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. Circulation, 2015, 131, 1006-1018. | 1.6 | 441 |
| 38 | Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59. | 1.2 | 432 |
| 39 | A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361. | 13.9 | 412 |
| 40 | Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88. | 2.5 | 405 |
| 41 | Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. European Respiratory Journal, 2010, 35, 105-111. | 3.1 | 398 |
| 42 | Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano, 2017, 11, 112-125. | 7.3 | 386 |
| 43 | Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553. | 1.0 | 371 |
| 44 | Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132. | 1.1 | 368 |
| 45 | Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D13-D21. | 1.2 | 367 |
| 46 | EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nature Genetics, 2014, 46, 65-69. | 9.4 | 351 |
| 47 | Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102. | 13.7 | 338 |
| 48 | Inflammation in Pulmonary Arterial Hypertension. Chest, 2012, 141, 210-221. | 0.4 | 333 |
| 49 | Immunosuppressive therapy in lupusâ€•and mixed connective tissue diseaseâ€“associated pulmonary arterial hypertension: A retrospective analysis of twentyâ€three cases. Arthritis and Rheumatism, 2008, 58, 521-531. | 6.7 | 321 |
| 50 | Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697. | 3.1 | 319 |
| 51 | Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Chest, 2006, 130, 182-189. | 0.4 | 316 |
| 52 | Epidemiology and treatment of pulmonary arterial hypertension. Nature Reviews Cardiology, 2017, 14, 603-614. | 6.1 | 310 |
| 53 | Dysregulated Reninâ€“Angiotensinâ€“Aldosterone System Contributes to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 780-789. | 2.5 | 309 |
| 54 | The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Trends in Immunology, 1999, 20, 528-533. | 7.5 | 308 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137. | 5.2 | 307 |
| 56 | Management of Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997. | 1.2 | 296 |
| 57 | Prognostic Factors for Survival in Human Immunodeficiency Virusâ€"associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1433-1439. | 2.5 | 295 |
| 58 | Pulmonary Veno-Occlusive Disease. Medicine (United States), 2008, 87, 220-233. | 0.4 | 295 |
| 59 | Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension. Circulation, 2013, 128, 2016-2025. | 1.6 | 294 |
| 60 | Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Human Pathology, 2007, 38, 893-902. | 1.1 | 291 |
| 61 | Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and longâ€term survival. Arthritis and Rheumatism, 2011, 63, 3522-3530. | 6.7 | 291 |
| 62 | Pulmonary veno-occlusive disease. European Respiratory Journal, 2016, 47, 1518-1534. | 3.1 | 289 |
| 63 | Revisiting <scp>T</scp>ype 2â€high and <scp>T</scp>ype 2â€low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy, 2017, 47, 161-175. | 1.4 | 287 |
| 64 | ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002828. | 3.1 | 287 |
| 65 | Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. European Respiratory Journal, 2020, 56, 2001634. | 3.1 | 284 |
| 66 | Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416. | 5.8 | 279 |
| 67 | Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. Circulation, 2014, 130, 2189-2208. | 1.6 | 278 |
| 68 | Deleterious Effects of Î²-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. Gastroenterology, 2006, 130, 120-126. | 0.6 | 277 |
| 69 | Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. European Heart Journal, 2006, 27, 589-595. | 1.0 | 272 |
| 70 | Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383. | 2.5 | 269 |
| 71 | Pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 33, 189-200. | 3.1 | 267 |
| 72 | Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an ACVRL1 (ALK1) Mutation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 851-861. | 2.5 | 259 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension. Circulation, 2006, 113, 1857-1864. | 1.6 | 257 |
| 74 | Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 311-321. | 2.5 | 249 |
| 75 | CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1419-1425. | 2.5 | 247 |
| 76 | Chemokine RANTES in Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 534-539. | 2.5 | 239 |
| 77 | Bosentan for the Treatment of Human Immunodeficiency Virusâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1212-1217. | 2.5 | 238 |
| 78 | Pulmonary Hypertension: CT of the Chest in Pulmonary Venoocclusive Disease. American Journal of Roentgenology, 2004, 183, 65-70. | 1.0 | 234 |
| 79 | Severe Pulmonary Hypertension in Histiocytosis X. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 216-223. | 2.5 | 231 |
| 80 | Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 35, 1286-1293. | 3.1 | 226 |
| 81 | Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, 2013, 8, 97. | 1.2 | 226 |
| 82 | Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215. | 13.9 | 224 |
| 83 | An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578. | 3.1 | 222 |
| 84 | Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2012, 40, 881-885. | 3.1 | 221 |
| 85 | Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643. | 2.5 | 220 |
| 86 | Overall asthma control: The relationship between current control and future risk. Journal of Allergy and Clinical Immunology, 2010, 125, 600-608.e6. | 1.5 | 219 |
| 87 | Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European Heart Journal, 2010, 31, 1898-1907. | 1.0 | 218 |
| 88 | Criteria for diagnosis of exercise pulmonary hypertension. European Respiratory Journal, 2015, 46, 728-737. | 3.1 | 213 |
| 89 | 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed ), 2016, 69, 177. | 0.4 | 210 |
| 90 | Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218. | 3.9 | 208 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757. | 1.6 | 205 |
| 92 | Survival and Prognostic Factors in Systemic Sclerosisâ€"Associated Pulmonary Hypertension: A Systematic Review and Metaâ€Analysis. Arthritis and Rheumatism, 2013, 65, 2412-2423. | 6.7 | 205 |
| 93 | Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. European Respiratory Journal, 2014, 44, 1275-1288. | 3.1 | 201 |
| 94 | BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Human Mutation, 2006, 27, 212-213. | 1.1 | 196 |
| 95 | Role of Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1041-1047. | 2.5 | 196 |
| 96 | Relationship between IL-4 and IL-5 mRNA Expression and Disease Severity in Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 704-708. | 2.5 | 191 |
| 97 | Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension. Circulation Research, 2004, 94, 1263-1270. | 2.0 | 187 |
| 98 | Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. European Respiratory Journal, 2018, 51, 1702523. | 3.1 | 186 |
| 99 | Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127. | 1.1 | 185 |
| 100 | Prevention of Gram-Negative Translocation Reduces the Severity of Hepatopulmonary Syndrome. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 514-517. | 2.5 | 179 |
| 101 | The threeâ€year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis and Rheumatism, 2009, 60, 1831-1839. | 6.7 | 179 |
| 102 | Omalizumab in Asthma: An Update on Recent Developments. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 525-536.e1. | 2.0 | 179 |
| 103 | Increased Pericyte Coverage Mediated by Endothelial-Derived Fibroblast Growth Factor-2 and Interleukin-6 Is a Source of Smooth Muscleâ€"Like Cells in Pulmonary Hypertension. Circulation, 2014, 129, 1586-1597. | 1.6 | 178 |
| 104 | Germline selection shapes human mitochondrial DNA diversity. Science, 2019, 364, . | 6.0 | 178 |
| 105 | Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. Journal of Clinical Investigation, 2009, 119, 512-523. | 3.9 | 177 |
| 106 | Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 2009, 119, 1518-1523. | 1.6 | 176 |
| 107 | C-Kitâ€"Positive Cells Accumulate in Remodeled Vessels of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 116-123. | 2.5 | 176 |
| 108 | A Proof-of-Concept, Randomized, Controlled Trial of Omalizumab in Patients With Severe, Difficult-to-Control, Nonatopic Asthma. Chest, 2013, 144, 411-419. | 0.4 | 176 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Recommendations for Screening and Detection of Connective Tissue Diseaseâ€“Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 3194-3201. | 6.7 | 175 |
| 110 | Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313. | 3.1 | 174 |
| 111 | French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095. | 3.1 | 173 |
| 112 | Basophils, eosinophils, and mast cells in atopic and nonatopic asthma and in late-phase allergic reactions in the lung and skin. Journal of Allergy and Clinical Immunology, 2000, 105, 99-107. | 1.5 | 172 |
| 113 | Pathogenesis of pulmonary arterial hypertension: lessons from cancer. European Respiratory Review, 2013, 22, 543-551. | 3.0 | 172 |
| 114 | Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 591-604. | 2.7 | 171 |
| 115 | Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191. | | 171 |
| 116 | RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1151-1158. | 2.5 | 165 |
| 117 | Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1681-1685. | 2.5 | 161 |
| 118 | Local expression of Ïµ germline gene transcripts and RNA for the Ïµ heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. Journal of Allergy and Clinical Immunology, 2001, 107, 686-692. | 1.5 | 161 |
| 119 | Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era. Chest, 2011, 140, 301-309. | 0.4 | 161 |
| 120 | Pulmonary Arterial Hypertension: A Rare Complication of Primary SjÃ¶gren Syndrome. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 | 0.4 | 160 |
| 121 | MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392. | 2.7 | 160 |
| 122 | Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704. | 1.6 | 155 |
| 123 | Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323. | 3.1 | 154 |
| 124 | PATHOBIOLOGY OF PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 451-458. | 0.8 | 153 |
| 125 | Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Human Mutation, 2011, 32, 1385-1389. | 1.1 | 152 |
| 126 | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048. | 3.1 | 152 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. Aids, 2010, 24, 67-75. | 1.0 | 149 |
| 128 | Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371. | 1.9 | 149 |
| 129 | Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology, 2008, 48, 304-308. | 0.9 | 148 |
| 130 | Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 983-997. | 2.5 | 144 |
| 131 | Severe eosinophilic asthma: a roadmap toÂconsensus. European Respiratory Journal, 2017, 49, 1700634. | 3.1 | 143 |
| 132 | Immune Dysregulation and Endothelial Dysfunction in Pulmonary Arterial Hypertension. Circulation, 2014, 129, 1332-1340. | 1.6 | 141 |
| 133 | Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385. | 1.6 | 141 |
| 134 | New Molecular Targets of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Chest, 2015, 147, 529-537. | 0.4 | 140 |
| 135 | Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmunity Reviews, 2017, 16, 1-9. | 2.5 | 140 |
| 136 | Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 873-884. | 5.2 | 139 |
| 137 | Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745. | 3.1 | 136 |
| 138 | Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 671-678. | 2.7 | 135 |
| 139 | Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. European Respiratory Journal, 2013, 41, 1302-1307. | 3.1 | 131 |
| 140 | Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis â€“ A <scp>EUFOREA</scp>â€<scp>ARIA</scp>â€<scp>EPOS</scp>â€<scp>AIRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305. | 2.7 | 130 |
| 141 | Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Annals of the Rheumatic Diseases, 2013, 72, 1940-1946. | 0.5 | 128 |
| 142 | MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2. | 1.5 | 128 |
| 143 | Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. European Respiratory Review, 2010, 19, 59-63. | 3.0 | 127 |
| 144 | Incidence and Prevalence of Chronic Thromboembolic Pulmonary Hypertension: From Acute to Chronic Pulmonary Embolism. Proceedings of the American Thoracic Society, 2006, 3, 564-567. | 3.5 | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362. | 0.3 | 126 |
| 146 | The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax, 2016, 71, 73-83. | 2.7 | 126 |
| 147 | Prioritised research agenda for prevention and control of chronic respiratory diseases. European Respiratory Journal, 2010, 36, 995-1001. | 3.1 | 125 |
| 148 | Autocrine Fibroblast Growth Factor-2 Signaling Contributes to Altered Endothelial Phenotype in Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 311-322. | 1.4 | 125 |
| 149 | Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology, 2011, 8, 526-538. | 6.1 | 125 |
| 150 | Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970. | 3.9 | 125 |
| 151 | Evidence for the Involvement of Type I Interferon in Pulmonary Arterial Hypertension. Circulation Research, 2014, 114, 677-688. | 2.0 | 124 |
| 152 | Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. European Journal of Cardio-thoracic Surgery, 2015, 47, e105-e110. | 0.6 | 124 |
| 153 | Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736. | 3.1 | 124 |
| 154 | Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. Lancet Respiratory Medicine,the, 2017, 5, 125-134. | 5.2 | 123 |
| 155 | Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238. | 5.2 | 122 |
| 156 | ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47. | 1.4 | 121 |
| 157 | An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258. | 2.5 | 121 |
| 158 | Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. European Respiratory Journal, 2010, 35, 1294-1302. | 3.1 | 119 |
| 159 | Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function inÂPulmonary Hypertension. Journal of the American College of Cardiology, 2015, 65, 668-680. | 1.2 | 119 |
| 160 | Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascular Pharmacology, 2008, 49, 113-118. | 1.0 | 118 |
| 161 | Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219. | 0.4 | 117 |
| 162 | RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 459-475. | 0.8 | 116 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. Annals of Thoracic Surgery, 2012, 94, 817-824. | 0.7 | 116 |
| 164 | Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 583-595. | 2.5 | 113 |
| 165 | Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1128-1134. | 2.5 | 112 |
| 166 | Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 915-917. | 3.1 | 111 |
| 167 | Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation, 2017, 136, 2022-2033. | 1.6 | 111 |
| 168 | Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465. | 3.1 | 111 |
| 169 | Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011. | 2.5 | 111 |
| 170 | Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2012, 40, 895-904. | 3.1 | 110 |
| 171 | Early detection of pulmonary arterial hypertension. Nature Reviews Cardiology, 2015, 12, 143-155. | 6.1 | 110 |
| 172 | Systemic sclerosisâ€“related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies. Arthritis and Rheumatism, 2011, 63, 2456-2464. | 6.7 | 109 |
| 173 | Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colonystimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and nonatopic controls. European Journal of Immunology, 1995, 25, 2727-2731. | 1.6 | 108 |
| 174 | Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis and Rheumatism, 2012, 64, 2995-3005. | 6.7 | 108 |
| 175 | Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Annals of the Rheumatic Diseases, 2017, 76, 422-426. | 0.5 | 108 |
| 176 | Anti-interleukin-5 therapy in severe asthma. European Respiratory Review, 2013, 22, 251-257. | 3.0 | 107 |
| 177 | Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Research and Therapy, 2006, 8, R114. | 1.6 | 106 |
| 178 | Angiopoietin/Tie2 Pathway Influences Smooth Muscle Hyperplasia in Idiopathic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1025-1033. | 2.5 | 106 |
| 179 | Post-acute COVID-19 syndrome. European Respiratory Review, 2022, 31, 210185. | 3.0 | 105 |
| 180 | Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Chest, 2012, 142, 1150-1157. | 0.4 | 104 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Safety Experience With Bosentan in 146 Children 2â€“11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program. Pediatric Research, 2008, 64, 200-204. | 1.1 | 103 |
| 182 | Mitomycin-Induced Pulmonary Veno-Occlusive Disease. Circulation, 2015, 132, 834-847. | 1.6 | 103 |
| 183 | Nitric Oxide Deficiency in Fenfluramine- and Dexfenfluramine-induced Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1061-1067. | 2.5 | 102 |
| 184 | Evaluation of Various Empirical Formulas for Estimating Mean Pulmonary Artery Pressure by Using Systolic Pulmonary Artery Pressure in Adults. Chest, 2009, 135, 760-768. | 0.4 | 102 |
| 185 | Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). European Respiratory Journal, 2016, 48, 1429-1441. | 3.1 | 102 |
| 186 | Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 2019, 41, 2041-2056.e5. | 1.1 | 102 |
| 187 | Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 717-726. | 5.2 | 99 |
| 188 | Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives. Chest, 1998, 114, 195S-199S. | 0.4 | 97 |
| 189 | Therapeutic Efficacy of AAV1.SERCA2a in Monocrotaline-Induced Pulmonary Arterial Hypertension. Circulation, 2013, 128, 512-523. | 1.6 | 97 |
| 190 | Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371. | 5.2 | 97 |
| 191 | Pulmonary hypertension in systemic sclerosis: different phenotypes. European Respiratory Review, 2017, 26, 170056. | 3.0 | 97 |
| 192 | Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy, 2009, 26, 813-825. | 1.3 | 96 |
| 193 | H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. Journal of Allergy and Clinical Immunology, 2007, 120, 827-834. | 1.5 | 95 |
| 194 | Pulmonary Artery Pressureâ€“Flow Relations after Prostacyclin in Primary Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 338-340. | 2.5 | 94 |
| 195 | Pulmonary veno-occlusive disease: Recent progress and current challenges. Respiratory Medicine, 2010, 104, S23-S32. | 1.3 | 94 |
| 196 | Early detection and management of pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 306-312. | 3.0 | 94 |
| 197 | Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854. | 2.5 | 94 |
| 198 | Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521. | 9.4 | 93 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103. | 3.1 | 92 |
| 200 | Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology, 2010, 49, 490-500. | 0.9 | 91 |
| 201 | Systemic Sclerosis-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1285-1293. | 2.5 | 91 |
| 202 | Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158. | 0.3 | 91 |
| 203 | Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2013, 41, 578-587. | 3.1 | 91 |
| 204 | Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1493-1499. | 2.5 | 90 |
| 205 | Medical Therapies for Chronic Thromboembolic Pulmonary Hypertension: An Evolving Treatment Paradigm. Proceedings of the American Thoracic Society, 2006, 3, 594-600. | 3.5 | 90 |
| 206 | Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. European Respiratory Journal, 2009, 34, 1348-1356. | 3.1 | 90 |
| 207 | Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. European Respiratory Journal, 2012, 39, 1405-1414. | 3.1 | 90 |
| 208 | Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875. | 3.1 | 90 |
| 209 | Clinical Characteristics and Survival in Systemic Sclerosis-Related Pulmonary Hypertension Associated With Interstitial Lung Disease. Chest, 2011, 140, 1016-1024. | 0.4 | 89 |
| 210 | Serotonin 5-HT2B receptors are required for bone-marrow contribution to pulmonary arterial hypertension. Blood, 2012, 119, 1772-1780. | 0.6 | 89 |
| 211 | Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217. | 3.1 | 89 |
| 212 | Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax, 1999, 54, 273-277. | 2.7 | 88 |
| 213 | Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. Journal of Allergy and Clinical Immunology, 2015, 135, 1457-1464.e4. | 1.5 | 88 |
| 214 | Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1273-1285. | 2.5 | 88 |
| 215 | Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?. Chest, 2013, 143, 398-405. | 0.4 | 87 |
| 216 | Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552. | 3.1 | 87 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44. | 1.4 | 87 |
| 218 | Development and implementation of guidelines in allergic rhinitis â€“ an ARIAâ€GA<sup>2</sup>LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221. | 2.7 | 85 |
| 219 | Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. European Respiratory Journal, 2011, 37, 813-822. | 3.1 | 85 |
| 220 | Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. European Respiratory Journal, 2011, 37, 1392-1399. | 3.1 | 85 |
| 221 | A Critical Role for p130<sup>Cas</sup> in the Progression of Pulmonary Hypertension in Humans and Rodents. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 666-676. | 2.5 | 85 |
| 222 | The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. Clinical Reviews in Allergy and Immunology, 2013, 44, 31-38. | 2.9 | 85 |
| 223 | Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 798-802. | 2.5 | 83 |
| 224 | Severe Chronic Allergic (and Related) Diseases: A Uniform Approach â€“ A MeDALL â€“ GA<sup>2</sup>LEN â€“ ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231. | 0.9 | 83 |
| 225 | Key Role of the Endothelial TGF-Î²2/ALK1/Endoglin Signaling Pathway in Humans and Rodents Pulmonary Hypertension. PLoS ONE, 2014, 9, e100310. | 1.1 | 83 |
| 226 | Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 910-924. | 1.6 | 83 |
| 227 | Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation, 2011, 121, 2888-2897. | 3.9 | 83 |
| 228 | External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419. | 3.1 | 83 |
| 229 | The CX3C chemokine fractalkine in allergic asthma and rhinitis. Journal of Allergy and Clinical Immunology, 2003, 112, 1139-1146. | 1.5 | 82 |
| 230 | High Occurrence of Hypoxemic Sleep Respiratory Disorders in Precapillary Pulmonary Hypertension and Mechanisms. Chest, 2013, 143, 47-55. | 0.4 | 82 |
| 231 | Contractile Dysfunction of Left Ventricular Cardiomyocytes in Patients With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2014, 64, 28-37. | 1.2 | 82 |
| 232 | Validation of two predictive models for survival in pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 152-164. | 3.1 | 82 |
| 233 | Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respiratory Research, 2010, 11, 73. | 1.4 | 81 |
| 234 | Drug-induced pulmonary arterial hypertension: a recent outbreak. European Respiratory Review, 2013, 22, 244-250. | 3.0 | 81 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855. | 2.0 | 81 |
| 236 | Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Annals of the Rheumatic Diseases, 2007, 66, 1610-1615. | 0.5 | 80 |
| 237 | Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22Î±â€targeted overexpression of the serotonin transporter. FASEB Journal, 2009, 23, 4135-4147. | 0.2 | 80 |
| 238 | Measuring asthma control: a comparison of three classification systems. European Respiratory Journal, 2010, 36, 269-276. | 3.1 | 80 |
| 239 | Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. European Respiratory Journal, 2012, 40, 630-640. | 3.1 | 80 |
| 240 | Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634. | 3.1 | 80 |
| 241 | Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. European Respiratory Journal, 2015, 46, 1721-1731. | 3.1 | 80 |
| 242 | Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585. | 2.5 | 80 |
| 243 | Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure. Radiology, 2002, 222, 782-788. | 3.6 | 79 |
| 244 | Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480. | 0.4 | 79 |
| 245 | Care pathways for the selection of a biologic in severe asthma. European Respiratory Journal, 2017, 50, 1701782. | 3.1 | 79 |
| 246 | Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139. | 1.8 | 78 |
| 247 | Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2007, 49, 1-5. | 0.8 | 77 |
| 248 | Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study. PLoS ONE, 2010, 5, e10128. | 1.1 | 77 |
| 249 | Nuclear Factor Î¤-B Is Activated in the Pulmonary Vessels of Patients with End-Stage Idiopathic Pulmonary Arterial Hypertension. PLoS ONE, 2013, 8, e75415. | 1.1 | 77 |
| 250 | Expression of the IL-4 receptor Î±-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjectsâ˜†â˜†â˜†â˜…â˜…â˜…. Journal of Allergy and Clinical Immunology, 1998, 102, 859-866. | 1.5 | 75 |
| 251 | Pulmonary hypertension associated with benfluorex exposure. European Respiratory Journal, 2012, 40, 1164-1172. | 3.1 | 75 |
| 252 | Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1747-1760. | 1.6 | 75 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389. | 1.6 | 75 |
| 254 | Non-invasive indices of right ventricular function are markers of ventricular-arterial coupling rather than ventricular contractility: insights from a porcine model of chronic pressure overload. European Heart Journal Cardiovascular Imaging, 2013, 14, 1140-1149. | 0.5 | 74 |
| 255 | Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948. | 1.6 | 74 |
| 256 | Strategic Plan for Lung Vascular Research. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1554-1562. | 2.5 | 73 |
| 257 | Omalizumab-induced decrease of FcÉ›RI expression in patients with severe allergic asthma. Respiratory Medicine, 2010, 104, 1608-1617. | 1.3 | 73 |
| 258 | Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1411-1418. | 2.5 | 72 |
| 259 | T-Helper 17 Cell Polarization in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1610-1620. | 0.4 | 72 |
| 260 | Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. European Respiratory Journal, 2019, 53, 1801371. | 3.1 | 72 |
| 261 | Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. European Respiratory Journal, 2020, 55, 1901592. | 3.1 | 71 |
| 262 | The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal, 2014, 44, 239-241. | 3.1 | 70 |
| 263 | An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355. | 2.5 | 70 |
| 264 | Characterization of Kcnk3 -Mutated Rat, a Novel Model of Pulmonary Hypertension. Circulation Research, 2019, 125, 678-695. | 2.0 | 70 |
| 265 | Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovascular Research, 2020, 116, 885-893. | 1.8 | 70 |
| 266 | Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications, 2014, 451, 8-14. | 1.0 | 69 |
| 267 | Chemokine Macrophage Inflammatory Protein-1Î± mRNA Expression in Lung Biopsy Specimens of Primary Pulmonary Hypertension. Chest, 1998, 114, 50S-51S. | 0.4 | 68 |
| 268 | Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. European Respiratory Journal, 2009, 34, 1100-1110. | 3.1 | 68 |
| 269 | Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 56, 715-720. | 1.2 | 68 |
| 270 | BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1668-1681. | 3.1 | 68 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Longâ€term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692. | 3.6 | 68 |
| 272 | Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. Chest, 2018, 153, 143-151. | 0.4 | 68 |
| 273 | Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802004. | 3.1 | 68 |
| 274 | Genes and Pulmonary Arterial Hypertension. Respiration, 2007, 74, 123-132. | 1.2 | 67 |
| 275 | Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respiratory Research, 2011, 12, 119. | 1.4 | 67 |
| 276 | Targeting transforming growth factor-Î² receptors in pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002341. | 3.1 | 67 |
| 277 | The 4th World Symposium on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S1-S2. | 1.2 | 66 |
| 278 | Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension. Circulation, 2000, 102, 2460-2462. | 1.6 | 65 |
| 279 | NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75. | 1.3 | 65 |
| 280 | Protein Changes Contributing to Right Ventricular Cardiomyocyte Diastolic Dysfunction in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2014, 3, e000716. | 1.6 | 65 |
| 281 | New chemokine targets for asthma therapy. Current Allergy and Asthma Reports, 2005, 5, 155-160. | 2.4 | 64 |
| 282 | Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108. | 0.4 | 64 |
| 283 | Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled. European Respiratory Review, 2017, 26, 170093. | 3.0 | 64 |
| 284 | IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1418-1429. | 2.0 | 64 |
| 285 | Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. Chest, 2016, 149, 1482-1493. | 0.4 | 63 |
| 286 | Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117. | 1.2 | 62 |
| 287 | Leptin signalling system as a target for pulmonary arterial hypertension therapy. European Respiratory Journal, 2015, 45, 1066-1080. | 3.1 | 62 |
| 288 | Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087. | 1.6 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2702-2714. | 2.0 | 62 |
| 290 | COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. Journal of Allergy and Clinical Immunology, 2021, 148, 361-367.e13. | 1.5 | 62 |
| 291 | Increased Expression of High Affinity IgE (Fc É› RI) Receptor- Î± Chain mRNA and Protein-bearing Eosinophils in Human Allergen-induced Atopic Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 233-240. | 2.5 | 61 |
| 292 | Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?. International Journal of Molecular Sciences, 2018, 19, 3162. | 1.8 | 61 |
| 293 | Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. International Immunology, 1996, 8, 1587-1594. | 1.8 | 60 |
| 294 | Pulmonary Hypertension Associated with Myeloproliferative Disorders: A Retrospective Study of Ten Cases. Respiration, 2008, 76, 295-302. | 1.2 | 60 |
| 295 | Pulmonary Hypertension in Patients With Neurofibromatosis Type I. Medicine (United States), 2011, 90, 201-211. | 0.4 | 60 |
| 296 | Corrigendum to: 'Guidelines for the diagnosis and treatment of pulmonary hypertension' [European Heart Journal (2009) 30, 2493-2537]. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2011, 32, 926-926. | 1.0 | 60 |
| 297 | TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications. European Respiratory Journal, 2017, 50, 1700754. | 3.1 | 60 |
| 298 | Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678. | 3.1 | 60 |
| 299 | An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thromboâ€embolic Pulmonary Hypertension and Lungâ€“Heart Transplantation. Hemoglobin, 2003, 27, 139-147. | 0.4 | 59 |
| 300 | Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review, 2019, 28, 190023. | 3.0 | 59 |
| 301 | Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respiratory Research, 2011, 12, 38. | 1.4 | 58 |
| 302 | Ca2+ handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2018, 118, 208-224. | 0.9 | 58 |
| 303 | Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1538-1544. | 1.4 | 57 |
| 304 | Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2019, 38, 833-842. | 0.3 | 57 |
| 305 | Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. European Respiratory Journal, 2020, 55, 1902345. | 3.1 | 57 |
| 306 | Serum Neopterin After Lung Transplantation. Chest, 1993, 103, 449-454. | 0.4 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. Arthritis and Rheumatism, 2008, 59, 867-875. | 6.7 | 56 |
| 308 | Use of Î²-Blockers in Pulmonary Hypertension. Circulation: Heart Failure, 2017, 10, . | 1.6 | 56 |
| 309 | Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respiratory Medicine,the, 2020, 8, 461-474. | 5.2 | 56 |
| 310 | Sleep-related breathing disorders and pulmonary hypertension. European Respiratory Journal, 2021, 57, 2002258. | 3.1 | 56 |
| 311 | INTRAPULMONARY PRODUCTION OF RANTES DURING REJECTION AND CMV PNEUMONITIS AFTER LUNG TRANSPLANTATION1. Transplantation, 1996, 61, 1757-1762. | 0.5 | 56 |
| 312 | Asthma and COVID-19: an update. European Respiratory Review, 2021, 30, 210152. | 3.0 | 56 |
| 313 | Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361. | 0.4 | 55 |
| 314 | Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. European Respiratory Journal, 2020, 55, 2000189. | 3.1 | 55 |
| 315 | Primary pulmonary hypertension: Current therapy. Progress in Cardiovascular Diseases, 2002, 45, 115-128. | 1.6 | 54 |
| 316 | Cytotoxic Cells and Granulysin in Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 189-196. | 2.5 | 54 |
| 317 | Tyrosine Kinase Inhibitors in Pulmonary Arterial Hypertension: A Double-Edge Sword?. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 714-724. | 0.8 | 54 |
| 318 | Pulmonary Arterial Hypertension in the Southern Hemisphere. Chest, 2015, 147, 495-501. | 0.4 | 54 |
| 319 | Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Circulation, 2019, 140, 1409-1425. | 1.6 | 54 |
| 320 | Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697. | 1.8 | 54 |
| 321 | Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology, 2010, 49, 940-944. | 0.9 | 53 |
| 322 | Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. European Respiratory Journal, 2012, 40, 75-83. | 3.1 | 53 |
| 323 | Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 139-149. | 3.1 | 53 |
| 324 | Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893. | 1.8 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Antifibroblast antibodies from systemic sclerosis patients bind to Î±-enolase and are associated with interstitial lung disease. Annals of the Rheumatic Diseases, 2010, 69, 428-433. | 0.5 | 51 |
| 326 | Cellular microparticles in the pathogenesis of pulmonary hypertension. European Respiratory Journal, 2013, 42, 272-279. | 3.1 | 51 |
| 327 | Human Immunodeficiency VirusnefSignature Sequences Are Associated with Pulmonary Hypertension. AIDS Research and Human Retroviruses, 2012, 28, 607-618. | 0.5 | 50 |
| 328 | Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876. | 0.4 | 50 |
| 329 | AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033. | 3.1 | 50 |
| 330 | Dasatinib increases endothelial permeability leading to pleural effusion. European Respiratory Journal, 2018, 51, 1701096. | 3.1 | 50 |
| 331 | Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655. | 0.3 | 50 |
| 332 | Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation. European Respiratory Journal, 2021, 58, 2004229. | 3.1 | 50 |
| 333 | Association of a KCNA5 gene polymorphism with systemic sclerosisâ€“associated pulmonary arterial hypertension in the European Caucasian population. Arthritis and Rheumatism, 2010, 62, 3093-3100. | 6.7 | 49 |
| 334 | Survivor bias and risk assessment. European Respiratory Journal, 2012, 40, 530-532. | 3.1 | 49 |
| 335 | Familial pulmonary arterial hypertension by KDR heterozygous loss of function. European Respiratory Journal, 2020, 55, 1902165. | 3.1 | 49 |
| 336 | Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discovery Today, 2014, 19, 1251-1256. | 3.2 | 48 |
| 337 | Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmunity Reviews, 2014, 13, 945-953. | 2.5 | 48 |
| 338 | Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092. | 3.0 | 48 |
| 339 | Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. Scientific Reports, 2018, 8, 1300. | 1.6 | 48 |
| 340 | Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation. Journal of Hypertension, 2018, 36, 1164-1177. | 0.3 | 48 |
| 341 | Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. Advances in Therapy, 2020, 37, 718-729. | 1.3 | 48 |
| 342 | Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29. | 1.4 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104. | 1.5 | 47 |
| 344 | Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS ONE, 2018, 13, e0197112. | 1.1 | 47 |
| 345 | Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. European Respiratory Journal, 2005, 26, 969-972. | 3.1 | 46 |
| 346 | Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. Chest, 2010, 137, 1297-1303. | 0.4 | 46 |
| 347 | Copper Dependence of Angioproliferation in Pulmonary Arterial Hypertension in Rats and Humans. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 582-591. | 1.4 | 46 |
| 348 | Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800. | 0.4 | 46 |
| 349 | ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190. | 2.7 | 46 |
| 350 | Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). European Respiratory Journal, 2022, 59, 2100396. | 3.1 | 46 |
| 351 | Update in Pulmonary Arterial Hypertension 2007. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 574-579. | 2.5 | 45 |
| 352 | Bromodomain and extraâ€terminal protein mimic <scp>JQ1</scp> decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. Respirology, 2017, 22, 157-164. | 1.3 | 45 |
| 353 | The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 860-868. | 2.5 | 45 |
| 354 | Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 586-594. | 2.5 | 45 |
| 355 | The role of combination therapy in managing pulmonary arterial hypertension. European Respiratory Review, 2014, 23, 469-475. | 3.0 | 44 |
| 356 | Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519. | 3.1 | 44 |
| 357 | Resting pulmonary artery pressure of 21â€“24â€…mmHg predicts abnormal exercise haemodynamics. European Respiratory Journal, 2016, 47, 1436-1444. | 3.1 | 44 |
| 358 | The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. European Respiratory Journal, 2019, 53, 1900038. | 3.1 | 44 |
| 359 | Screening strategies for pulmonary arterial hypertension. European Heart Journal Supplements, 2019, 21, K9-K20. | 0.0 | 44 |
| 360 | Lineage Tracing Reveals the Dynamic Contribution of Pericytes to the Blood Vessel Remodeling in Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 766-782. | 1.1 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Relation between inflammation and symptoms in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 354-367. | 2.7 | 43 |
| 362 | Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations. European Respiratory Journal, 2014, 44, 1069-1072. | 3.1 | 43 |
| 363 | Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. Chest, 2018, 154, 872-881. | 0.4 | 43 |
| 364 | Evaluation and management of pulmonary arterial hypertension. Respiratory Medicine, 2020, 171, 106099. | 1.3 | 43 |
| 365 | Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. Radiology, 2021, 298, 531-549. | 3.6 | 43 |
| 366 | Activation of Macrophages and Cytotoxic Cells during Cytomegalovirus Pneumonia Complicating Lung Transplantations. The American Review of Respiratory Disease, 1992, 145, 1178-1184. | 2.9 | 42 |
| 367 | Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. Presse Medicale, 2014, 43, e345-e363. | 0.8 | 42 |
| 368 | Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 267-279. | 1.3 | 42 |
| 369 | RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164. | 1.4 | 42 |
| 370 | Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. European Respiratory Journal, 2021, 57, 2004455. | 3.1 | 42 |
| 371 | Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. Oncotarget, 2017, 8, 52995-53016. | 0.8 | 42 |
| 372 | Pulmonary veno-occlusive disease: advances in clinical management and treatments. Expert Review of Respiratory Medicine, 2011, 5, 217-231. | 1.0 | 41 |
| 373 | Scleroderma Lung Disease. Clinical Reviews in Allergy and Immunology, 2011, 40, 104-116. | 2.9 | 41 |
| 374 | IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605. | 0.5 | 41 |
| 375 | Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116. | 3.1 | 41 |
| 376 | A Proof of Concept for the Detection and Classification of Pulmonary Arterial Hypertension through Breath Analysis with a Sensor Array. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 756-759. | 2.5 | 40 |
| 377 | Pulmonary arterial hypertension in idiopathic inflammatory myopathies. Medicine (United States), 2016, 95, e4911. | 0.4 | 40 |
| 378 | COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020. | 1.1 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. European Respiratory Journal, 2020, 55, 1902340. | 3.1 | 40 |
| 380 | Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. European Respiratory Review, 2020, 29, 190089. | 3.0 | 40 |
| 381 | Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. PLoS ONE, 2015, 10, e0131940. | 1.1 | 40 |
| 382 | POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respiratory Medicine, 2007, 101, 353-355. | 1.3 | 39 |
| 383 | A critical analysis of survival in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 218-222. | 3.0 | 39 |
| 384 | Risk assessment in pulmonary arterial hypertension. European Respiratory Review, 2016, 25, 390-398. | 3.0 | 39 |
| 385 | Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. Annals of Allergy, Asthma and Immunology, 2020, 124, 190-196. | 0.5 | 39 |
| 386 | IN SITU PRODUCTION OF INTERLEUKIN-6 WITHIN HUMAN LUNG ALLOGRAFTS DISPLAYING REJECTION OR CYTOMEGALOVIRUS PNEUMONIA. Transplantation, 1993, 56, 623-627. | 0.5 | 38 |
| 387 | N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respiratory Research, 2014, 15, 65. | 1.4 | 38 |
| 388 | Systolic and Mean Pulmonary Artery Pressures. Chest, 2015, 147, 943-950. | 0.4 | 38 |
| 389 | Right ventricular reserve in a piglet model of chronic pulmonary hypertension. European Respiratory Journal, 2015, 45, 709-717. | 3.1 | 38 |
| 390 | Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). Current Rheumatology Reports, 2016, 18, 10. | 2.1 | 38 |
| 391 | Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. European Respiratory Journal, 2020, 56, 2001808. | 3.1 | 38 |
| 392 | Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation, 2021, 144, 52-73. | 1.6 | 38 |
| 393 | Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 411-420. | 0.8 | 37 |
| 394 | Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. Journal of Rheumatology, 2010, 37, 105-115. | 1.0 | 37 |
| 395 | Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension. European Respiratory Journal, 2015, 45, 1495-1498. | 3.1 | 37 |
| 396 | Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Archives of Cardiovascular Diseases, 2017, 110, 303-316. | 0.7 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2017, 36, 1234-1242. | 0.3 | 37 |
| 398 | Respiratory effects of trichloroethylene. Respiratory Medicine, 2018, 134, 47-53. | 1.3 | 37 |
| 399 | Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilanceâ€“pharmacodynamic study. European Respiratory Journal, 2019, 53, 1802472. | 3.1 | 37 |
| 400 | Pulmonary Arterial Histologic Lesions in Patients With COPD With Severe Pulmonary Hypertension. Chest, 2019, 156, 33-44. | 0.4 | 37 |
| 401 | Current Insights on the Pathogenesis of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 355-364. | 0.8 | 36 |
| 402 | Single-Cell Study of Two Rat Models of Pulmonary Arterial Hypertension Reveals Connections to Human Pathobiology and Drug Repositioning. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1006-1022. | 2.5 | 36 |
| 403 | Effect of different asthma treatments on risk of cold-related exacerbations. European Respiratory Journal, 2011, 38, 584-593. | 3.1 | 35 |
| 404 | Pre-implantation genetic diagnosis in pulmonary arterial hypertension due toBMPR2mutation: Figure 1â€“. European Respiratory Journal, 2012, 39, 1534-1535. | 3.1 | 35 |
| 405 | Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2015, 46, 1851-1853. | 3.1 | 35 |
| 406 | Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. Drug Safety, 2016, 39, 287-294. | 1.4 | 35 |
| 407 | Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1102-1111. | 2.5 | 35 |
| 408 | Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Annals of the Rheumatic Diseases, 2010, 69, 1360-1363. | 0.5 | 34 |
| 409 | Estimating Right Ventricular Stroke Work and the Pulsatile Work Fraction in Pulmonary Hypertension. Chest, 2013, 143, 1343-1350. | 0.4 | 34 |
| 410 | Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 457-467. | 0.3 | 34 |
| 411 | Resident PW1 <sup>+</sup> Progenitor Cells Participate in Vascular Remodeling During Pulmonary Arterial Hypertension. Circulation Research, 2016, 118, 822-833. | 2.0 | 34 |
| 412 | Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405. | 1.4 | 34 |
| 413 | Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. Expert Opinion on Therapeutic Targets, 2017, 21, 181-190. | 1.5 | 34 |
| 414 | Review: Therapeutic advances in pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2008, 2, 249-265. | 1.0 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. Chest, 2015, 147, 1385-1394. | 0.4 | 33 |
| 416 | Multimodal Imaging Mass Spectrometry to Identify Markers of Pulmonary Arterial Hypertension in Human Lung Tissue Using MALDI-ToF, ToF-SIMS, and Hybrid SIMS. Analytical Chemistry, 2020, 92, 12079-12087. | 3.2 | 33 |
| 417 | Hyperplasia of Pulmonary Artery Smooth Muscle Cells Is Causally Related to Overexpression of the Serotonin Transporter in Primary Pulmonary Hypertension. Chest, 2002, 121, 97S-98S. | 0.4 | 32 |
| 418 | Pulmonary arterial hypertension masquerading as severe refractory asthma. European Respiratory Journal, 2008, 32, 513-516. | 3.1 | 32 |
| 419 | Update in Pulmonary Hypertension 2008. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 650-656. | 2.5 | 32 |
| 420 | Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. European Respiratory Journal, 2017, 49, 1601897. | 3.1 | 32 |
| 421 | Pulmonary Hypertension in Parenchymal Lung Diseases. Chest, 2018, 153, 217-223. | 0.4 | 32 |
| 422 | Severe T2-high asthma in the biologics era: European experts' opinion. European Respiratory Review, 2019, 28, 190054. | 3.0 | 32 |
| 423 | Lung transplantation for sarcoidosis: outcome and prognostic factors. European Respiratory Journal, 2021, 58, 2003358. | 3.1 | 32 |
| 424 | Prostacyclin for pulmonary arterial hypertension. The Cochrane Library, 2019, 2019, CD012785. | 1.5 | 32 |
| 425 | Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre. European Respiratory Review, 2009, 18, 272-290. | 3.0 | 31 |
| 426 | Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension. European Respiratory Journal, 2010, 35, 6-8. | 3.1 | 31 |
| 427 | Small platelet microparticle levels are increased in pulmonary arterial hypertension. European Journal of Clinical Investigation, 2013, 43, 64-71. | 1.7 | 31 |
| 428 | Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. European Respiratory Journal, 2016, 48, 254-257. | 3.1 | 31 |
| 429 | Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2002463. | 3.1 | 31 |
| 430 | Sex and gender in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 200330. | 3.0 | 31 |
| 431 | Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European Journal of Pediatrics, 2002, 161, S93-S96. | 1.3 | 30 |
| 432 | Pulmonary hypertension complicating sarcoidosis. Presse Medicale, 2012, 41, e303-e316. | 0.8 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Cooperation between human fibrocytes and endothelial colony-forming cells increases angiogenesis via the CXCR4 pathway. Thrombosis and Haemostasis, 2014, 112, 1002-1013. | 1.8 | 30 |
| 434 | Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 342-355. | 2.5 | 30 |
| 435 | Rare respiratory diseases are ready for primetime: from Rare Disease Day to the European Reference Networks. European Respiratory Journal, 2017, 49, 1700085. | 3.1 | 30 |
| 436 | An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension. Nature Communications, 2021, 12, 1720. | 5.8 | 30 |
| 437 | Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. Aids, 2005, 19, 1239-1240. | 1.0 | 29 |
| 438 | Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. European Respiratory Journal, 2010, 36, 202-204. | 3.1 | 29 |
| 439 | Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411. | 0.7 | 29 |
| 440 | Factors predicting outcome after pulmonary endarterectomy. PLoS ONE, 2018, 13, e0198198. | 1.1 | 29 |
| 441 | Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, . | 1.6 | 29 |
| 442 | L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Presse Medicale, 2013, 42, 507-510. | 0.8 | 28 |
| 443 | Drugs induced pulmonary arterial hypertension. Presse Medicale, 2013, 42, e303-e310. | 0.8 | 28 |
| 444 | Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Medicale, 2014, 43, e293-e304. | 0.8 | 28 |
| 445 | Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. International Journal of Cardiology, 2014, 172, 561-567. | 0.8 | 28 |
| 446 | Interferon-induced pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 415-420. | 1.2 | 28 |
| 447 | Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respiratory Medicine, 2019, 154, 69-75. | 1.3 | 28 |
| 448 | Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279. | 3.1 | 28 |
| 449 | How to Assess Effectiveness of Biologics for Asthma and What Steps to Take When There Is Not Benefit. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1081-1088. | 2.0 | 28 |
| 450 | Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332. | 3.1 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Inhibition of B cellâ€“dependent lymphoid follicle formation prevents lymphocytic bronchiolitis after lung transplantation. JCI Insight, 2019, 4, . | 2.3 | 28 |
| 452 | Systematic Analysis of Blood Cell Transcriptome in End-Stage Chronic Respiratory Diseases. PLoS ONE, 2014, 9, e109291. | 1.1 | 28 |
| 453 | WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165. | 3.0 | 28 |
| 454 | Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 716-721. | 0.3 | 28 |
| 455 | Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H769-H777. | 1.5 | 27 |
| 456 | Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26. | 1.0 | 27 |
| 457 | Implication of Potassium Channels in the Pathophysiology of Pulmonary Arterial Hypertension. Biomolecules, 2020, 10, 1261. | 1.8 | 27 |
| 458 | Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. European Respiratory Journal, 2022, 60, 2103181. | 3.1 | 27 |
| 459 | Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 751-760. | 2.5 | 27 |
| 460 | Human Î³-Herpesviruses Epstein-Barr Virus and Human Herpesvirus-8 Are Not Detected in the Lungs of Patients With Severe Pulmonary Arterial Hypertension. Chest, 2011, 139, 1310-1316. | 0.4 | 26 |
| 461 | ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clinical Genetics, 2012, 82, 173-179. | 1.0 | 26 |
| 462 | Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. Chest, 2013, 144, 1512-1520. | 0.4 | 26 |
| 463 | Chronic thromboembolic pulmonary hypertension. Presse Medicale, 2015, 44, e409-e416. | 0.8 | 26 |
| 464 | Risk assessment in pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1800279. | 3.1 | 26 |
| 465 | Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENTâ€1/â€2 studies. Pulmonary Circulation, 2018, 8, 1-4. | 0.8 | 26 |
| 466 | Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486. | 3.1 | 26 |
| 467 | Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 295-304. | 2.9 | 26 |
| 468 | Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovascular Research, 2022, 118, 1805-1820. | 1.8 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension. Chest, 2022, 161, 219-231. | 0.4 | 26 |
| 470 | Mediators involved in HIV-related pulmonary arterial hypertension. Aids, 2008, 22, S41-S47. | 1.0 | 25 |
| 471 | Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. European Respiratory Journal, 2010, 36, 1209-1211. | 3.1 | 25 |
| 472 | Pulmonary veno-occlusive disease: The bÃªte noire of pulmonary hypertension in connective tissue diseases?. Presse Medicale, 2011, 40, e87-e100. | 0.8 | 25 |
| 473 | Impression, Sunset. Circulation, 2013, 127, 1098-1100. | 1.6 | 25 |
| 474 | Asthma: still a promising future?. European Respiratory Review, 2014, 23, 405-407. | 3.0 | 25 |
| 475 | Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. Proteomics, 2016, 16, 2637-2649. | 1.3 | 25 |
| 476 | A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. Journal of Cardiac Failure, 2017, 23, 29-35. | 0.7 | 25 |
| 477 | Pulmonary hypertension associated with neurofibromatosis type 1. European Respiratory Review, 2018, 27, 180053. | 3.0 | 25 |
| 478 | Allergen-induced recruitment of FcÏƒRI+ eosinophils in human atopic skin. European Journal of Immunology, 1997, 27, 1236-1241. | 1.6 | 24 |
| 479 | Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine, 2010, 16, S1-S9. | 1.2 | 24 |
| 480 | Progress in Pulmonary Arterial Hypertension Pathology: Relighting a Torch Inside the Tunnel. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 210-212. | 2.5 | 24 |
| 481 | Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. Respiratory Research, 2015, 16, 114. | 1.4 | 24 |
| 482 | Heritable pulmonary hypertension: from bench to bedside. European Respiratory Review, 2017, 26, 170037. | 3.0 | 24 |
| 483 | Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108. | 3.1 | 24 |
| 484 | Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131. | 1.4 | 24 |
| 485 | Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. Journal of Heart and Lung Transplantation, 2021, 40, 1009-1018. | 0.3 | 24 |
| 486 | Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 9-19. | 0.2 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Ciclesonide: a novel inhaled corticosteroid. Expert Opinion on Investigational Drugs, 2004, 13, 1349-1360. | 1.9 | 23 |
| 488 | Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S. | 0.4 | 23 |
| 489 | Fatal rupture of pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasis and severe PAH. European Respiratory Review, 2009, 18, 42-46. | 3.0 | 23 |
| 490 | Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2011, 12, 1585-1596. | 0.9 | 23 |
| 491 | Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. European Respiratory Journal, 2013, 41, 8-9. | 3.1 | 23 |
| 492 | Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 1195-1198. | 3.1 | 23 |
| 493 | CardioPulse ArticlesWhat's new in the European Society of Cardiology/European Respiratory Society Pulmonary Hypertension Guidelines?The Ten Commandments for 2015 European Society of Cardiologyâ€“European Respiratory Society Guidelines on Pulmonary HypertensionNewEHJinternational editorial board membersEHJSupplementâ€”the Heart of the Matter, UPDATE: Table 1. European Heart Journal, 2016, 37, 4-11. | 1.0 | 23 |
| 494 | No genetic association detected with mepolizumab efficacy in severe asthma. Respiratory Medicine, 2017, 132, 178-180. | 1.3 | 23 |
| 495 | Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401. | 1.8 | 23 |
| 496 | Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220. | 1.3 | 23 |
| 497 | Sildenafil for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 6-7. | 2.5 | 22 |
| 498 | Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1193-1205. | 1.5 | 22 |
| 499 | Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519. | 0.3 | 22 |
| 500 | Poor Subpleural Perfusion Predicts Failure After Balloon Pulmonary Angioplasty for Nonoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2018, 154, 521-531. | 0.4 | 22 |
| 501 | Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679. | 0.2 | 22 |
| 502 | Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 223-8. | 0.2 | 22 |
| 503 | Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803. | 3.1 | 22 |
| 504 | The association between resting and mild-to-moderate exercise pulmonary artery pressure. European Respiratory Journal, 2012, 39, 313-318. | 3.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Riociguat for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study (PATENT-1). Chest, 2012, 142, 1027A. | 0.4 | 21 |
| 506 | T-type Ca2+ channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. Biochimica Et Biophysica Acta - Molecular Cell Research, 2017, 1864, 1631-1641. | 1.9 | 21 |
| 507 | Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. European Respiratory Review, 2018, 27, 180004. | 3.0 | 21 |
| 508 | Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 4105. | 1.8 | 21 |
| 509 | Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272. | 3.1 | 21 |
| 510 | Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 2021, 12, 7104. | 5.8 | 21 |
| 511 | Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. Respiration, 2013, 85, 471-477. | 1.2 | 20 |
| 512 | KCNK3: new gene target for pulmonary hypertension?. Expert Review of Respiratory Medicine, 2014, 8, 385-387. | 1.0 | 20 |
| 513 | Right ventricular plasticity in a porcine model of chronic pressure overload. Journal of Heart and Lung Transplantation, 2014, 33, 194-202. | 0.3 | 20 |
| 514 | New pharmacotherapy options for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2015, 16, 2113-2131. | 0.9 | 20 |
| 515 | Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension. Journal of Medicinal Chemistry, 2018, 61, 2725-2736. | 2.9 | 20 |
| 516 | Rapid Contour-based Segmentation for <sup>18</sup>F-FDG PET Imaging of Lung Tumors by Using ITK-SNAP: Comparison to Expert-based Segmentation. Radiology, 2018, 288, 277-284. | 3.6 | 20 |
| 517 | Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. Journal of Heart and Lung Transplantation, 2018, 37, 1102-1110. | 0.3 | 20 |
| 518 | In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. Respiratory Research, 2020, 21, 186. | 1.4 | 20 |
| 519 | Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488. | 1.8 | 20 |
| 520 | Use of Amplatzer Fenestrated Atrial Septal Defect Device in a Child with Familial Pulmonary Hypertension. Pediatric Cardiology, 2006, 27, 759-762. | 0.6 | 19 |
| 521 | Current management approaches to portopulmonary hypertension. International Journal of Clinical Practice, 2011, 65, 11-18. | 0.8 | 19 |
| 522 | Severe Pulmonary Hypertension Associated With Emphysema. Chest, 2012, 142, 1654-1658. | 0.4 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | Evidence of endogenous volatile organic compounds as biomarkers of diseases in alveolar breath. Annales Pharmaceutiques Francaises, 2013, 71, 203-215. | 0.4 | 19 |
| 524 | An Update on Medical Therapy for Pulmonary Arterial Hypertension. Current Hypertension Reports, 2013, 15, 614-622. | 1.5 | 19 |
| 525 | Should we use gait speed in COPD, FEV‹sub›1‹/sub›in frailty and dyspnoea in both?. European Respiratory Journal, 2016, 48, 315-319. | 3.1 | 19 |
| 526 | Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?. Current Hypertension Reports, 2017, 19, 86. | 1.5 | 19 |
| 527 | Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. American Journal of Pathology, 2019, 189, 1159-1175. | 1.9 | 19 |
| 528 | Excitation-contraction coupling and relaxation alteration in right ventricular remodelling caused by pulmonary arterial hypertension. Archives of Cardiovascular Diseases, 2020, 113, 70-84. | 0.7 | 19 |
| 529 | A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797. | 0.4 | 19 |
| 530 | Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1449-1460. | 2.5 | 19 |
| 531 | Severe pulmonary arterial hypertension in type 1 glycogen storage disease. European Journal of Pediatrics, 2002, 161, S93-S96. | 1.3 | 18 |
| 532 | TGFÎ² receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. Annals of the Rheumatic Diseases, 2012, 71, 1900-1903. | 0.5 | 18 |
| 533 | Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147. | 0.4 | 18 |
| 534 | The Thousand Faces of Leptin in the Lung. Chest, 2021, 159, 239-248. | 0.4 | 18 |
| 535 | Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. European Respiratory Journal, 2021, 58, 2101090. | 3.1 | 18 |
| 536 | Serotonin Transporter and Receptors in Various Forms of Human Pulmonary Hypertension. Chest, 2005, 128, 552S-553S. | 0.4 | 17 |
| 537 | Enhanced glucocorticoidâ€induced leucine zipper in dendritic cells induces allergenâ€specific regulatory ‹scp›CD‹/scp›4‹sup›+‹/sup›‹scp›T‹/scp›â€cells in respiratory allergies. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 624-631. | 2.7 | 17 |
| 538 | Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2209-2221. | 2.9 | 17 |
| 539 | Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration, 2018, 95, 244-250. | 1.2 | 17 |
| 540 | Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174. | 2.5 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. International Journal of Molecular Sciences, 2019, 20, 3575. | 1.8 | 17 |
| 542 | The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. International Journal of Molecular Sciences, 2019, 20, 1527. | 1.8 | 17 |
| 543 | An update on sarcoidosis-associated pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2020, 26, 582-590. | 1.2 | 17 |
| 544 | Pulmonary capillary haemangiomatosis: a distinct entity?. European Respiratory Review, 2020, 29, 190168. | 3.0 | 17 |
| 545 | Life-threatening PPHN refractory to nitric oxide: proposal for a rational therapeutic algorithm. European Journal of Pediatrics, 2021, 180, 2379-2387. | 1.3 | 17 |
| 546 | Endothelin Receptor Antagonists. Handbook of Experimental Pharmacology, 2013, 218, 199-227. | 0.9 | 17 |
| 547 | Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119. | 0.6 | 17 |
| 548 | Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nature Clinical Practice Rheumatology, 2005, 1, 93-101. | 3.2 | 16 |
| 549 | Severe Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 551-552. | 2.5 | 16 |
| 550 | Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 645-653. | 0.8 | 16 |
| 551 | GINA 2015: the latest iteration of a magnificent journey. European Respiratory Journal, 2015, 46, 579-582. | 3.1 | 16 |
| 552 | A prospective study of the 6â€…min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naÃ¯ve systemic sclerosis-associated pulmonary arterial hypertension. Annals of the Rheumatic Diseases, 2016, 75, 1457-1465. | 0.5 | 16 |
| 553 | Genetics of pulmonary hypertension in the clinic. Current Opinion in Pulmonary Medicine, 2017, 23, 386-391. | 1.2 | 16 |
| 554 | Validation of a risk assessment instrument for pulmonary arterial hypertension. European Heart Journal, 2018, 39, 4182-4185. | 1.0 | 16 |
| 555 | Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. Blood Reviews, 2019, 37, 100579. | 2.8 | 16 |
| 556 | Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653. | 3.1 | 16 |
| 557 | Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021. | 1.1 | 16 |
| 558 | COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583. | 2.5 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Montelukast in guidelines and beyond. Advances in Therapy, 2009, 26, 575-587. | 1.3 | 15 |
| 560 | Pharmacokinetic evaluation of continuous intravenous epoprostenol. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1587-1598. | 1.5 | 15 |
| 561 | The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238. | 3.0 | 15 |
| 562 | Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure. Respiration, 2013, 85, 464-470. | 1.2 | 15 |
| 563 | A Critical Appraisal of the Updated 2014 Nice Pulmonary Hypertension Classification System. Canadian Journal of Cardiology, 2015, 31, 367-374. | 0.8 | 15 |
| 564 | Novel targets of omalizumab in asthma. Current Opinion in Pulmonary Medicine, 2017, 23, 56-61. | 1.2 | 15 |
| 565 | Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. Journal of Heart and Lung Transplantation, 2017, 36, 386-398. | 0.3 | 15 |
| 566 | A genome-wide association analysis identifies PDE1A\|DNAJC10 locus on chromosome 2 associated with idiopathic pulmonary arterial hypertension in a Japanese population. Oncotarget, 2017, 8, 74917-74926. | 0.8 | 15 |
| 567 | Right heart catheterisation is still a fundamental part of the follow-up assessment of pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800738. | 3.1 | 15 |
| 568 | Lysyl oxidaseâ€”a possible role in systemic sclerosisâ€“associated pulmonary hypertension: a multicentre study. Rheumatology, 2019, 58, 1547-1555. | 0.9 | 15 |
| 569 | Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585. | 3.1 | 15 |
| 570 | A novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism. Cardiovascular Research, 2020, 116, 1500-1513. | 1.8 | 15 |
| 571 | Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS ONE, 2020, 15, e0243961. | 1.1 | 15 |
| 572 | 2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. Russian Journal of Cardiology, 2016, , 5-64. | 0.4 | 15 |
| 573 | Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. European Respiratory Journal, 2022, 60, 2103130. | 3.1 | 15 |
| 574 | An emerging phenotype of pulmonary arterial hypertension patients carryingSOX17variants. European Respiratory Journal, 2022, 60, 2200656. | 3.1 | 15 |
| 575 | Mutations de gÃ¨nes codant pour des rÃ©cepteurs du TGF-Î² (BMPR-2 et ALK-1) dans les hypertensions artÃ©rielles pulmonaires primitives. SociÃ©tÃ© De Biologie Journal, 2002, 196, 53-58. | 0.3 | 14 |
| 576 | Asthma management: Are GINA guidelines appropriate for daily clinical practice?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2005, 14, 294-302. | 2.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | A decade of achievement in pulmonary hypertension. European Respiratory Review, 2011, 20, 215-217. | 3.0 | 14 |
| 578 | Development of prognostic tools in pulmonary arterial hypertension: Lessons from modern day registries. Thrombosis and Haemostasis, 2012, 108, 1049-1060. | 1.8 | 14 |
| 579 | Pulmonary complications of type 1 neurofibromatosis. Revue Des Maladies Respiratoires, 2016, 33, 460-473. | 1.7 | 14 |
| 580 | Managing asthma in the era of biological therapies. Lancet Respiratory Medicine,the, 2017, 5, 376-378. | 5.2 | 14 |
| 581 | Proteomic Analysis of KCNK3 Loss of Expression Identified Dysregulated Pathways in Pulmonary Vascular Cells. International Journal of Molecular Sciences, 2020, 21, 7400. | 1.8 | 14 |
| 582 | Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207. | 0.4 | 14 |
| 583 | Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066. | 3.1 | 14 |
| 584 | Pulmonary hypertension related to drugs and toxins. Current Opinion in Cardiology, 1999, 14, 437. | 0.8 | 14 |
| 585 | The Right Tools at the Right Time. Chest, 2006, 130, 29S-40S. | 0.4 | 13 |
| 586 | EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€“. European Respiratory Journal, 2012, 39, 1549-1550. | 3.1 | 13 |
| 587 | New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension. European Respiratory Review, 2013, 22, 495-502. | 3.0 | 13 |
| 588 | CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity. Clinical Pharmacology and Therapeutics, 2014, 95, 583-585. | 2.3 | 13 |
| 589 | A roadmap for management of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 54, 1901295. | 3.1 | 13 |
| 590 | Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension. Chest, 2019, 155, 991-998. | 0.4 | 13 |
| 591 | Survival Improved in Patients AgedÂâ‰ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. Chest, 2020, 157, 945-954. | 0.4 | 13 |
| 592 | Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241. | 1.3 | 13 |
| 593 | Recent advances in the management of pulmonary hypertension with interstitial lung disease. European Respiratory Review, 2022, 31, 210220. | 3.0 | 13 |
| 594 | Biologics in asthma: difficulties and drawbacks. Expert Opinion on Biological Therapy, 2008, 8, 1921-1928. | 1.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 595 | Vasodilators in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 202-203. | 2.5 | 12 |
| 596 | Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270. | 3.0 | 12 |
| 597 | Global effort against rare and orphan diseases. European Respiratory Review, 2012, 21, 171-172. | 3.0 | 12 |
| 598 | Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. Chest, 2016, 150, 256-258. | 0.4 | 12 |
| 599 | Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 537-541. | 2.5 | 12 |
| 600 | Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 406-408. | 2.5 | 12 |
| 601 | Functional interaction between PDGFÎ² and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L445-L455. | 1.3 | 12 |
| 602 | Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852. | 2.5 | 12 |
| 603 | Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208. | 3.1 | 12 |
| 604 | Integrating haemodynamics identifies an extreme pulmonary hypertension phenotype. European Respiratory Journal, 2021, 58, 2004625. | 3.1 | 12 |
| 605 | Interplay of sex hormones and long-term right ventricular adaptation in a Dutch PAH-cohort. Journal of Heart and Lung Transplantation, 2022, 41, 445-457. | 0.3 | 12 |
| 606 | Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine, 2010, 104, S74-S80. | 1.3 | 11 |
| 607 | ERS publications: the flagship and the fleet. European Respiratory Journal, 2012, 40, 535-537. | 3.1 | 11 |
| 608 | Plasma Levels of High-Density Lipoprotein Cholesterol Are Not Associated with Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 107-107. | 2.5 | 11 |
| 609 | Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. Progress in Respiratory Research, 2012, , 85-93. | 0.1 | 11 |
| 610 | Idiopathic Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 560-567. | 0.8 | 11 |
| 611 | Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy. European Respiratory Journal, 2014, 43, 641-643. | 3.1 | 11 |
| 612 | The ambition of the European Respiratory Journal: chapter 3. European Respiratory Journal, 2015, 45, 1-6. | 3.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 613 | Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting Î²2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respiratory Medicine, 2018, 141, 111-120. | 1.3 | 11 |
| 614 | Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 942-946. | 2.7 | 11 |
| 615 | The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis. Lancet Rheumatology, The, 2021, 3, e149-e159. | 2.2 | 11 |
| 616 | PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet Journal of Rare Diseases, 2021, 16, 196. | 1.2 | 11 |
| 617 | Endothelin Receptor Antagonists. Handbook of Experimental Pharmacology, 2013, , 199-227. | 0.9 | 11 |
| 618 | Temporal Asthma Patterns Using Repeated Questionnaires over 13 Years in a Large French Cohort of Women. PLoS ONE, 2013, 8, e65090. | 1.1 | 11 |
| 619 | The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats. PLoS ONE, 2013, 8, e77073. | 1.1 | 11 |
| 620 | Role of Store-Operated Ca2+ Entry in the Pulmonary Vascular Remodeling Occurring in Pulmonary Arterial Hypertension. Biomolecules, 2021, 11, 1781. | 1.8 | 11 |
| 621 | Understanding the Role of CD4+CD25<sup>high</sup> (So-Called Regulatory) T Cells in Idiopathic Pulmonary Arterial Hypertension. Respiration, 2008, 75, 253-256. | 1.2 | 10 |
| 622 | Association of pulmonary aspergilloma and allergic bronchopulmonary aspergillosis. European Respiratory Review, 2010, 19, 349-351. | 3.0 | 10 |
| 623 | Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension. PLoS ONE, 2015, 10, e0134221. | 1.1 | 10 |
| 624 | Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476. | 0.8 | 10 |
| 625 | Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347. | 0.3 | 10 |
| 626 | Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 647-656. | 0.3 | 10 |
| 627 | Homoarginine predicts mortality in treatment-naive patients with pulmonary arterial hypertension. International Journal of Cardiology, 2016, 217, 12-15. | 0.8 | 10 |
| 628 | Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892. | 0.4 | 10 |
| 629 | Ultra-rare disease: an European perspective. European Respiratory Review, 2020, 29, 200195. | 3.0 | 10 |
| 630 | Right Ventricle Remodeling Metabolic Signature in Experimental Pulmonary Hypertension Models of Chronic Hypoxia and Monocrotaline Exposure. Cells, 2021, 10, 1559. | 1.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2021, 22, 9105. | 1.8 | 10 |
| 632 | Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585. | 0.4 | 10 |
| 633 | SUR1 as a New Therapeutic Target for Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2022, , . | 1.4 | 10 |
| 634 | Pulmonary Venoocclusive Disease and Failure of Specific Therapy. Chest, 2009, 136, 1181. | 0.4 | 9 |
| 635 | Predicting Survival in Pulmonary Arterial Hypertension. Chest, 2011, 139, 1263-1264. | 0.4 | 9 |
| 636 | Novel Medical Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2013, 34, 867-880. | 0.8 | 9 |
| 637 | The ambition of the European Respiratory Journal. European Respiratory Journal, 2013, 41, 1-2. | 3.1 | 9 |
| 638 | Telomere Maintenance Is a Critical Determinant in the Physiopathology of Pulmonary Hypertension. Journal of the American College of Cardiology, 2015, 66, 1942-1943. | 1.2 | 9 |
| 639 | Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 686-700. | 0.8 | 9 |
| 640 | Controversies and opportunities in severe asthma. Current Opinion in Pulmonary Medicine, 2018, 24, 83-93. | 1.2 | 9 |
| 641 | Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosusâ€associated pulmonary arterial hypertension. ESC Heart Failure, 2019, 6, 1322-1325. | 1.4 | 9 |
| 642 | Hospital burden of pulmonary arterial hypertension in France. PLoS ONE, 2019, 14, e0221211. | 1.1 | 9 |
| 643 | An insider view on the World Symposium on Pulmonary Hypertension. Lancet Respiratory Medicine,the, 2019, 7, 484-485. | 5.2 | 9 |
| 644 | Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SVâ€INHIBITION study design. ESC Heart Failure, 2020, 7, 747-756. | 1.4 | 9 |
| 645 | Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension. Chest, 2005, 128, 622S. | 0.4 | 8 |
| 646 | Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research and Therapy, 2011, 13, 114. | 1.6 | 8 |
| 647 | Whistleblowers. European Respiratory Journal, 2011, 38, 510-511. | 3.1 | 8 |
| 648 | Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure. Chest, 2011, 140, 1066-1068. | 0.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 649 | Circulating fibrocytes and pulmonary arterial hypertension. European Respiratory Journal, 2012, 39, 210-212. | 3.1 | 8 |
| 650 | Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. European Respiratory Journal, 2015, 46, 283-286. | 3.1 | 8 |
| 651 | Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. European Respiratory Journal, 2017, 50, 1701319. | 3.1 | 8 |
| 652 | Pulmonary arterial hypertension registries: past, present and into the future. European Respiratory Review, 2019, 28, 190128. | 3.0 | 8 |
| 653 | Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854. | 0.9 | 8 |
| 654 | The â€˜great waitâ€™ for diagnosis in pulmonary arterial hypertension. Respirology, 2020, 25, 790-792. | 1.3 | 8 |
| 655 | Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission and role for pre-test probability scores and home treatment. European Respiratory Journal, 2021, 58, 2101033. | 3.1 | 8 |
| 656 | Right ventricle dysfunction in patients with acute pulmonary embolism supposedly at low risk for death: when evidence-based medicine rescues clinical practice. European Heart Journal, 2021, 42, 3200-3202. | 1.0 | 8 |
| 657 | Association between Leflunomide and Pulmonary Hypertension. Annals of the American Thoracic Society, 2021, 18, 1306-1315. | 1.5 | 8 |
| 658 | Neonatal diagnosis of HIV infection. Lancet, The, 1991, 338, 631. | 6.3 | 7 |
| 659 | Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 677-683. | 0.4 | 7 |
| 660 | Letter by Montani et al Regarding Article, â€œElevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertensionâ€• Circulation, 2011, 123, e614; author reply e615. | 1.6 | 7 |
| 661 | The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2014, 8, 84-92. | 1.0 | 7 |
| 662 | Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300. | 3.1 | 7 |
| 663 | A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. European Respiratory Review, 2016, 25, 93-96. | 3.0 | 7 |
| 664 | Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527. | 3.1 | 7 |
| 665 | Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1532-1542.e5. | 0.4 | 7 |
| 666 | Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466. | 3.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 667 | Success and continuous growth of the ERS clinical research collaborations. European Respiratory Journal, 2021, 58, 2102527. | 3.1 | 7 |
| 668 | Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology, 2010, 28, S47-52. | 0.4 | 7 |
| 669 | Lung transplantation in HIV-positive patients: a European retrospective cohort study. European Respiratory Journal, 2022, 60, 2200189. | 3.1 | 7 |
| 670 | Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. British Journal of Clinical Pharmacology, 2022, 88, 5227-5237. | 1.1 | 7 |
| 671 | PERFORIN AND GRANZYME B GENE-EXPRESSING CELLS IN BRONCHOALVEOLAR LAVAGE FLUIDS FROM LUNG ALLOGRAFT RECIPIENTS DISPLAYING CYTOMEGALOVIRUS PNEUMONITIS. Transplantation, 1994, 57, 1289-1292. | 0.5 | 6 |
| 672 | Immunologic Therapeutic Interventions in Asthma. Clinics in Chest Medicine, 2012, 33, 585-597. | 0.8 | 6 |
| 673 | The ambition of the European Respiratory Journal: chapter 2. European Respiratory Journal, 2014, 43, 1-2. | 3.1 | 6 |
| 674 | Perceived 10-year change in respiratory health: Reliability and predictive ability. Respiratory Medicine, 2015, 109, 188-199. | 1.3 | 6 |
| 675 | Blood Eosinophils and Serum IgE Predict Response to Omalizumab in Patients with Severe Allergic Asthma: Innovate Trial Post-Hoc Analysis. Journal of Allergy and Clinical Immunology, 2016, 137, AB16. | 1.5 | 6 |
| 676 | Clinical trials: registration and transparency. European Respiratory Journal, 2016, 47, 1342-1344. | 3.1 | 6 |
| 677 | Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension. A New Chapter of the Story. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 704-706. | 2.5 | 6 |
| 678 | POINT: Should Initial Combination Therapy Be the Standard of Care in Pulmonary Arterial Hypertension? Yes. Chest, 2019, 156, 1039-1042. | 0.4 | 6 |
| 679 | Pulmonary arterial hypertension in systemic sclerosis. Presse Medicale, 2021, 50, 104062. | 0.8 | 6 |
| 680 | European Respiratory Society clinical practice guidelines: methodological guidance. ERJ Open Research, 2022, 8, 00655-2021. | 1.1 | 6 |
| 681 | Finding Pulmonary Arterial Hypertensionâ€"Switching to Offense to Mitigate Disease Burden. JAMA Cardiology, 2022, 7, 369. | 3.0 | 6 |
| 682 | Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. Annals of Cardiothoracic Surgery, 2022, 11, 143-150. | 0.6 | 6 |
| 683 | Perioperative approach to precapillary pulmonary hypertension in non-cardiac non-obstetric surgery. European Respiratory Review, 2021, 30, 210166. | 3.0 | 6 |
| 684 | Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293. | 0.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 685 | The fifth world symposium on pulmonary hypertension will REVEAL the impact of registries. European Respiratory Review, 2012, 21, 4-5. | 3.0 | 5 |
| 686 | Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. Circulation, 2012, 125, 2045-2047. | 1.6 | 5 |
| 687 | You say goodbye, and I say hello!. European Respiratory Review, 2012, 21, 265-266. | 3.0 | 5 |
| 688 | Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2015, 46, 1211-1214. | 3.1 | 5 |
| 689 | Toward better management of rare and orphan pulmonary diseases. European Respiratory Journal, 2016, 47, 1334-1335. | 3.1 | 5 |
| 690 | Lung transplantation for mitomycin-induced pulmonary veno-occlusive disease. Presse Medicale, 2017, 46, 1223-1225. | 0.8 | 5 |
| 691 | Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. International Journal of Clinical Pharmacy, 2018, 40, 790-794. | 1.0 | 5 |
| 692 | Guidance production before evidence generation for critical issues: the example of COVID-19. European Respiratory Review, 2020, 29, 200310. | 3.0 | 5 |
| 693 | Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. Chest, 2020, 158, 2602-2609. | 0.4 | 5 |
| 694 | Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. British Journal of Anaesthesia, 2020, 125, e466-e468. | 1.5 | 5 |
| 695 | Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. Archivos De Bronconeumologia, 2020, 56, 578-585. | 0.4 | 5 |
| 696 | Lung transplantation in neonates and infants: ESPNIC survey of European neonatologists and pediatric intensivists. European Journal of Pediatrics, 2021, 180, 295-298. | 1.3 | 5 |
| 697 | The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7, 00941-2020. | 1.1 | 5 |
| 698 | Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study. Pulmonary Circulation, 2021, 11, 1-9. | 0.8 | 5 |
| 699 | Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiographyâ€based cluster analysis. American Journal of Hematology, 2021, 96, 1166-1175. | 2.0 | 5 |
| 700 | Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. Journal of Asthma and Allergy, 2021, Volume 14, 1129-1138. | 1.5 | 5 |
| 701 | Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. European Respiratory Journal, 2021, 58, 2101576. | 3.1 | 5 |
| 702 | PlateletâEDerived Growth Factor Receptor Type Î± Activation Drives Pulmonary Vascular Remodeling Via Progenitor Cell Proliferation and Induces Pulmonary Hypertension. Journal of the American Heart Association, 2022, 11, e023021. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 703 | Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 210161. | 3.0 | 5 |
| 704 | Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. European Respiratory Journal, 2022, 60, 2200107. | 3.1 | 5 |
| 705 | New Formula for Predicting Mean Pulmonary Artery Pressure. Chest, 2005, 128, 467. | 0.4 | 4 |
| 706 | Update on the European Respiratory Review. European Respiratory Journal, 2010, 36, 993-994. | 3.1 | 4 |
| 707 | Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2011, 38, 2419-2427. | 1.0 | 4 |
| 708 | Future perspectives on rare pulmonary diseases and rare presentations of common disorders. European Respiratory Review, 2013, 22, 199-201. | 3.0 | 4 |
| 709 | Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€. Circulation, 2016, 133, e592-3. | 1.6 | 4 |
| 710 | Targeting immunoglobulin E in non-atopic asthma: crossing the red line?. European Respiratory Journal, 2016, 48, 1538-1540. | 3.1 | 4 |
| 711 | The ambition of the European Respiratory Journal: chapter 4. European Respiratory Journal, 2016, 47, 1-4. | 3.1 | 4 |
| 712 | Pulmonary veno-occlusive disease as an occupational lung disease. Lancet Respiratory Medicine,the, 2017, 5, e19. | 5.2 | 4 |
| 713 | Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. Rheumatology, 2017, 56, v33-v37. | 0.9 | 4 |
| 714 | Are indexed values better for defining exercise pulmonary hypertension?. European Respiratory Journal, 2017, 50, 1700240. | 3.1 | 4 |
| 715 | Biomarker-based corticosteroid adjustment in severe asthma: a modified Delphi consensus. ERJ Open Research, 2018, 4, 00081-2018. | 1.1 | 4 |
| 716 | Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation, 2020, 10, 1-10. | 0.8 | 4 |
| 717 | Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary venoâ€occlusive disease. Pulmonary Circulation, 2020, 10, 1-4. | 0.8 | 4 |
| 718 | Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 675-677. | 2.5 | 4 |
| 719 | Pulmonary Endarterectomy in Patients With Myeloproliferative Neoplasms. Chest, 2022, 161, 552-556. | 0.4 | 4 |
| 720 | Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. International Journal of Clinical Pharmacy, 2020, 42, 1128-1138. | 1.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 721 | Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. Frontiers in Medicine, 2022, 9, 851935. | 1.2 | 4 |
| 722 | Sildenafil for Pulmonary Hypertension in Pregnancy?. Anesthesiology, 2006, 104, 383-383. | 1.3 | 3 |
| 723 | Prise enÂcharge diagnostique etÂthÃ©rapeutique deÂl'hypertension artÃ©rielle pulmonaire. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2007, 16, 294-301. | 0.1 | 3 |
| 724 | Clinical Year in Review IV. Proceedings of the American Thoracic Society, 2012, 9, 204-209. | 3.5 | 3 |
| 725 | Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. European Respiratory Review, 2014, 23, 260-263. | 3.0 | 3 |
| 726 | Response to Letter Regarding Article, â€œAdvances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertensionâ€• Circulation, 2015, 132, e154. | 1.6 | 3 |
| 727 | Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. International Journal of Cardiology, 2015, 184, 763-765. | 0.8 | 3 |
| 728 | To stress or not to stress? Exercise pulmonary haemodynamic testing in systemic sclerosis. European Respiratory Journal, 2016, 48, 1549-1552. | 3.1 | 3 |
| 729 | Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients. Leukemia and Lymphoma, 2017, 58, 2875-2879. | 0.6 | 3 |
| 730 | Response to the article â€œSorafenib as a potential strategy for refractory pulmonary arterial hypertensionâ€• Pulmonary Pharmacology and Therapeutics, 2017, 45, 11-12. | 1.1 | 3 |
| 731 | Rare pulmonary diseases: a common fight. European Respiratory Review, 2017, 26, 170059. | 3.0 | 3 |
| 732 | Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration. European Respiratory Journal, 2020, 55, 2001047. | 3.1 | 3 |
| 733 | Reversible pulmonary hypertension associated with multivisceral Whipple's disease. European Respiratory Journal, 2021, 57, 2003132. | 3.1 | 3 |
| 734 | The evolution of the European Respiratory Journal: weathering the publishing pandemic. European Respiratory Journal, 2021, 57, 2100084. | 3.1 | 3 |
| 735 | Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562. | 2.0 | 3 |
| 736 | Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400. | 2.6 | 3 |
| 737 | Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12. | 0.8 | 3 |
| 738 | Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). , 2018, , . | | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 739 | Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. ERJ Open Research, 2022, 8, 00419-2021. | 1.1 | 3 |
| 740 | Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2102388. | 3.1 | 3 |
| 741 | Progression of Pulmonary Venoâ€occlusive Disease Without Pulmonary Hypertension. Pulmonary Circulation, 2022, 12, e12046. | 0.8 | 3 |
| 742 | The Ten Commandments for 2015 European Society of Cardiologyâ€"European Respiratory Society Guidelines on Pulmonary Hypertension. European Heart Journal, 2016, 37, 5. | 1.0 | 3 |
| 743 | Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort. European Respiratory Journal, 0, , 2102897. | 3.1 | 3 |
| 744 | Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension. Expert Opinion on Pharmacotherapy, 2006, 7, 1133-1138. | 0.9 | 2 |
| 745 | Screening for Portopulmonary Hypertension with Transthoracic Echocardiography: Implications for Early Mortality Associated with Liver Transplantation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 378-379. | 2.5 | 2 |
| 746 | GuÃa de prÃ¡ctica clÃnica para el diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia (English Ed ), 2009, 62, 1464.e1-1464.e58. | 0.4 | 2 |
| 747 | Pulmonary Arterial Hypertension and HIV and Other Viral Infections. Progress in Respiratory Research, 2012, , 105-112. | 0.1 | 2 |
| 748 | Introduction: Devising a Prognostic Score for Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, S1-S2. | 0.7 | 2 |
| 749 | Everything you always wanted to know about sarcoidosisâ€¦ but were afraid to ask. Presse Medicale, 2012, 41, e273-e274. | 0.8 | 2 |
| 750 | A study of magnesium deficiency in human and experimental pulmonary hypertension. Magnesium Research, 2012, 25, 21-27. | 0.4 | 2 |
| 751 | Could the Cochin risk prediction score be applied in daily practice to predict pulmonary hypertension in systemic sclerosis? Comment on the article by Meune et al. Arthritis and Rheumatism, 2012, 64, 2051-2052. | 6.7 | 2 |
| 752 | Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236. | 0.4 | 2 |
| 753 | Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respiratory Medicine,the, 2018, 6, 7-8. | 5.2 | 2 |
| 754 | Outpatient management of patients with low-risk pulmonary embolism: another piece of evidence. European Heart Journal, 2019, 41, 519-521. | 1.0 | 2 |
| 755 | Response by Guignabert et al to Letter Regarding Article, â€œSelective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertensionâ€. Circulation Research, 2019, 124, e82-e83. | 2.0 | 2 |
| 756 | Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario. European Respiratory Journal, 2020, 56, 2002281. | 3.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 757 | Description, Staging and Quantification of Pulmonary Artery Angiophagy in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension. Biomedicines, 2020, 8, 493. | 1.4 | 2 |
| 758 | Looking forward: key initiatives to improve the care of rare diseases and streamline the delivery of medicines and vaccines in Europe. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L616-L618. | 1.3 | 2 |
| 759 | Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?. Metabolites, 2021, 11, 784. | 1.3 | 2 |
| 760 | Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023. | 0.8 | 2 |
| 761 | HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?. European Heart Journal, 2022, 43, 2209-2211. | 1.0 | 2 |
| 762 | Loss of cAbl Tyrosine Kinase in Pulmonary Arterial Hypertension Causes Dysfunction of Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2022, , . | 1.4 | 2 |
| 763 | To be or not to beâ€¦ treated with initial combination therapy, that is the (PAH) question. European Respiratory Journal, 2022, 59, 2200390. | 3.1 | 2 |
| 764 | Screening for pulmonary veno-occlusive disease in heterozygous EIF2AK4 variant carriers. European Respiratory Journal, 2022, 60, 2200760. | 3.1 | 2 |
| 765 | Bronchial immunoglobulin E production in intrinsic asthma. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 229-231. | 0.1 | 1 |
| 766 | Bosentan for the treatment of scleroderma. Future Rheumatology, 2006, 1, 549-562. | 0.2 | 1 |
| 767 | The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228a-229. | 2.5 | 1 |
| 768 | Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2010, 138, 462-463. | 0.4 | 1 |
| 769 | The changing face of respiratory physiology: 20 years of progress within the ERS: Clinical Physiology and Integrative Biology Assembly contribution to the celebration of 20 years of the ERS. European Respiratory Journal, 2010, 35, 945-948. | 3.1 | 1 |
| 770 | Current Challenges in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 549-550. | 0.8 | 1 |
| 771 | Translational research in pulmonary hypertension: challenge and opportunity. European Respiratory Journal, 2014, 43, 325-328. | 3.1 | 1 |
| 772 | Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35. | 0.1 | 1 |
| 773 | Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376. | 0.8 | 1 |
| 774 | Pulmonary hypertension. Current Opinion in Pulmonary Medicine, 2016, 22, 399. | 1.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 775 | The ambition of the European Respiratory Journal continues: chapter 5. European Respiratory Journal, 2017, 49, 1602393. | 3.1 | 1 |
| 776 | Novel Treatments for Airway Disease. New England Journal of Medicine, 2017, 377, 595-598. | 13.9 | 1 |
| 777 | Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia, 2018, 37, 759-761. | 0.2 | 1 |
| 778 | Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4â€aminopyridine. Fundamental and Clinical Pharmacology, 2019, 33, 426-427. | 1.0 | 1 |
| 779 | Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e90-e91. | 2.5 | 1 |
| 780 | Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension?. European Respiratory Journal, 2020, 55, 2000700. | 3.1 | 1 |
| 781 | Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000962. | 3.1 | 1 |
| 782 | Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÃ¨ce de RÃ©sistance?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 524-525. | 2.5 | 1 |
| 783 | Lung and heart-lung transplantation for children with PAH: Dramatic benefits from the implementation of a high-priority allocation program in France. Journal of Heart and Lung Transplantation, 2021, 40, 652-661. | 0.3 | 1 |
| 784 | A <scp>CELSR1</scp> variant in a patient with pulmonary arterial hypertension. Clinical Genetics, 2021, 100, 771-772. | 1.0 | 1 |
| 785 | Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19. Lancet Respiratory Medicine,the, 2021, 9, e75-e76. | 5.2 | 1 |
| 786 | Pulmonary Veno-occlusive Disease and Pulmonary Capillary Hemangiomatosis. Respiratory Medicine, 2020, , 89-108. | 0.1 | 1 |
| 787 | Pulmonary hypertension associated with sarcoidosis. , 2012, , 166-181. | | 1 |
| 788 | Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , . | | 1 |
| 789 | Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study). , 2019, , . | | 1 |
| 790 | Inflammation in Pulmonary Arterial Hypertension. , 2012, , 213-229. | | 1 |
| 791 | Pulmonary Hypertension in Orphan Lung Diseases. , 2015, , 529-539. | | 1 |
| 792 | Rare pulmonary disease and orphan drugs: a path to the future. European Respiratory Review, 2019, 28, 190115. | 3.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 793 | Multimodality Imaging of Pulmonary Hypertension: Prognostication of Therapeutic Outcomes. Medical Radiology, 2021, , 225-257. | 0.0 | 1 |
| 794 | Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134. | 0.1 | 1 |
| 795 | Sex and gender in lung health and disease: more than just Xs and Ys. European Respiratory Review, 2021, 30, 210217. | 3.0 | 1 |
| 796 | Response to: Life-threatening PPHN refractory to NO: therapeutic algorithm. European Journal of Pediatrics, 2022, 181, 425-426. | 1.3 | 1 |
| 797 | Pulsatile pulmonary artery pressure in a large animal model of chronic thromboembolic pulmonary hypertension: Similarities and differences with human data. Pulmonary Circulation, 2022, 12, e12017. | 0.8 | 1 |
| 798 | Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. , 0, , 89-104. | | 1 |
| 799 | Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 367-368. | 0.8 | 0 |
| 800 | Chronic thromboembolic pulmonary hypertension (CTEPH): specific disease characteristics and similarities to idiopathic pulmonary arterial hypertension. Clinical Research in Cardiology Supplements, 2010, 5, 12-15. | 2.0 | 0 |
| 801 | Pulmonary arterial hypertension and the state of limbo. European Respiratory Review, 2010, 19, 264-265. | 3.0 | 0 |
| 802 | Quarterly Medical Review: Pulmonary involvement in systemic diseases. Presse Medicale, 2011, 40, e23-e24. | 0.8 | 0 |
| 803 | Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 65-75. | 0.1 | 0 |
| 804 | Drug- and Toxin-Induced Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 76-84. | 0.1 | 0 |
| 805 | Pulmonary Veno-Occlusive Disease. Progress in Respiratory Research, 2012, , 149-160. | 0.1 | 0 |
| 806 | Omalizumab in the treatment of severe allergic (IgEâ€mediated) asthma: an update on recent developments. Clinical and Translational Allergy, 2013, 3, O12. | 1.4 | 0 |
| 807 | Reply: The Reninâ€“Angiotensin System in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1139-1140. | 2.5 | 0 |
| 808 | Thorax Innovation (TORINO). Presse Medicale, 2013, 42, e301-e302. | 0.8 | 0 |
| 809 | Does Circulating IL-17 Identify a Subset of Patients With Idiopathic Pulmonary Arterial Hypertension?: Response. Chest, 2015, 148, e132-e133. | 0.4 | 0 |
| 810 | Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 811 | Novelties in the Treatment of Pulmonary Hypertension. Archivos De Bronconeumologia, 2017, 53, 235-236. | 0.4 | 0 |
| 812 | Evolving Concepts in Pulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 559-560. | 0.8 | 0 |
| 813 | Prostacyclin for pulmonary hypertension. The Cochrane Library, 2017, , . | 1.5 | 0 |
| 814 | A unique event for the francophone respiratory community. European Respiratory Journal, 2017, 50, 1701479. | 3.1 | 0 |
| 815 | Reply to Frachon: Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1364-1365. | 2.5 | 0 |
| 816 | Lessons from pulmonary hypertension registries. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 759-761. | 0.2 | 0 |
| 817 | Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 820-821. | 2.5 | 0 |
| 818 | Hypertension pulmonaire et connectivites. Revue Du Rhumatisme Monographies, 2018, 85, 210-220. | 0.0 | 0 |
| 819 | Rebuttal From Drs Humbert and Lau. Chest, 2019, 156, 1045-1046. | 0.4 | 0 |
| 820 | Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. , 2021, , 301-316. | | 0 |
| 821 | Pulmonary hypertension associated with neurofibromatosis type 2. Pulmonary Circulation, 2021, 11, 1-4. | 0.8 | 0 |
| 822 | Comment on: Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype. European Respiratory Journal, 2021, 58, 2101365. | 3.1 | 0 |
| 823 | Pulmonary hypertension. Annals of Allergy, Asthma and Immunology, 2021, 127, 512-513. | 0.5 | 0 |
| 824 | Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , . | 2.5 | 0 |
| 825 | Polymorphisme du gÃ¨ne codant pour le transporteur de la sÃ©rotonine et hypertension artÃ©rielle pulmonaire. Medecine/Sciences, 2002, 18, 395-397. | 0.0 | 0 |
| 826 | Late Limited Systemic Sclerosis Patient Who Develops Shortness of Breath on Exertion. , 2011, , 127-137. | | 0 |
| 827 | Pulmonary hypertension associated with portal hypertension. , 2011, , 245-250. | | 0 |
| 828 | Pulmonary hypertension related to appetite suppressants. , 2011, , 236-244. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 829 | Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis. , 2012, , 182-193. | | 0 |
| 830 | Pulmonary hypertension in pulmonary Langerhansâ€™ cell histiocytosis. , 2012, , 161-165. | | 0 |
| 831 | Acute Right Heart Failure in Pulmonary Hypertension. , 2014, , 261-275. | | 0 |
| 832 | Hematopoietic Stem Cells and Chronic Hypoxia-Induced Pulmonary Vascular Remodelling. Pancreatic Islet Biology, 2015, , 241-256. | 0.1 | 0 |
| 833 | Clinical Assessment of Pulmonary Hypertension. , 2017, , 403-409. | | 0 |
| 834 | Architecture gÃ©nÃ©tique de lâ€™hypertension pulmonaire : des gÃ¨nes aux mÃ©dicaments. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 879-893. | 0.0 | 0 |
| 835 | Interstitial lung diseases in the 2020s. Presse Medicale, 2020, 49, 104022. | 0.8 | 0 |
| 836 | Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. , 2020, , 167-183. | | 0 |
| 837 | Right heart failure. , 0, , 32-47. | | 0 |
| 838 | ERS statement on chronic thromboembolic pulmonary hypertension. Pulmonologiya, 2022, 32, 13-52. | 0.2 | 0 |
| 839 | Commemorating World Tuberculosis Day 2022: recent ERJ articles of critical relevance to ending TB and saving lives. European Respiratory Journal, 2022, 59, 2200149. | 3.1 | 0 |
| 840 | Some take-home messages from the 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs. European Respiratory Review, 2021, 30, 210258. | 3.0 | 0 |
| 841 | Title is missing!. , 2020, 15, e0243961. | | 0 |
| 842 | Title is missing!. , 2020, 15, e0243961. | | 0 |
| 843 | Title is missing!. , 2020, 15, e0243961. | | 0 |
| 844 | Title is missing!. , 2020, 15, e0243961. | | 0 |
| 845 | The Long March to a Cure for Pulmonary Hypertension. JACC Asia, 2022, 2, 215-217. | 0.5 | 0 |
| 846 | Erythrocytes are altered in pulmonary arterial hypertension. European Respiratory Journal, 0, , 2200506. | 3.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 847 | Knowledge exchange between patient and pharmacist: a mixed methods study to explore the role of pharmacists in patient education and counselling in asthma and pulmonary arterial hypertension. Annales Pharmaceutiques Francaises, 2022, , . | 0.4 | 0 |
| 848 | Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report. Respiratory Medicine and Research, 2022, , 100943. | 0.4 | 0 |